GlassScriptPhysician profile
Kyle D Robertson
NPI 1336559004
$3,151.84
in general payments reported to CMS, 2019-2025
19 companies · $291 in 2025
The $291 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.34 · 2020: $29.78 · 2021: $41.37 · 2022: $675 · 2023: $1,276 · 2024: $812 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,365 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,364.80 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $531.61 | 2022-2025 | Epclusa, Livdelzi |
| Abbvie INC. | $515.93 | 2019-2024 | Rinvoq, Skyrizi, Viberzi |
| Intercept Pharmaceuticals, INC. | $413.64 | 2022-2024 | Ocaliva |
| Genzyme Corporation | $255.83 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $227.63 | 2022-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $205.34 | 2020-2024 | Xifaxan |
| Medtronic, INC. | $161.16 | 2023 | Interstim |
| Ipsen Biopharmaceuticals, INC | $124.74 | 2024 | Iqirvo |
| Janssen Biotech, INC. | $108.37 | 2022-2024 | Stelara |
| Madrigal Pharmaceuticals | $91.74 | 2025 | Rezdiffra |
| Eisai INC. | $77.32 | 2024 | |
| Nestle Healthcare Nutrition INC. | $76.52 | 2022-2023 | |
| Daiichi Sankyo INC. | $73.35 | 2023-2024 | Injectafer |
| Organon LLC | $61.09 | 2024-2025 | Hadlima, Renflexis |
| Olympus America INC. | $60.36 | 2021-2023 | Evis Exera Lll Colonovideoscope |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $48.39 | 2022-2023 | Amjevita |
| Pfizer INC. | $43.72 | 2023 | |
| Alnylam Pharmaceuticals INC. | $40.83 | 2023 | Givlaari |
| Merck Sharp & Dohme LLC | $34.27 | 2022-2023 | Dificid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Robertson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.